10-K.Info (Beta Test) Courtesy of Short Sands, LLC | |||||||||||||
| |||||||||||||
|
10-K.Info (Beta Test) Courtesy of Short Sands, LLC | |||
REGENERON PHARMACEUTICALS, INC. | |||
Ticker: REGN Fiscal Year: 2013 | |||
CONSOLIDATED STATEMENTS OF CASH FLOWS | |||
Period Ending Dec 31, 2013 10-K (Filed: Feb 13, 2014) | |||
| (In Thousands, except shares in actual) | |||
| 12 Months Ended | 12 Months Ended | 12 Months Ended | |
| Dec 31, 2013 | Dec 31, 2012 | Dec 31, 2011 | |
| Cash flows from operating activities: | |||
| Net income (loss) | $ 424,362 | 750,269 | (221,760) |
| Adjustments to reconcile net income (loss) to net cash provided by (used in) operating activities: | |||
| Depreciation and amortization | 41,204 | 36,940 | 31,082 |
| Non-cash compensation expense | 198,399 | 94,157 | 56,094 |
| Non-cash interest expense | 23,061 | 22,925 | 5,101 |
| Other non-cash charges and expenses, net | 23,690 | 34,049 | 6,714 |
| Deferred taxes | 63,601 | (340,156) | 0 |
| Changes in assets and liabilites | |||
| Increase in Sanofi and trade accounts receivable | (198,658) | (590,085) | (21,118) |
| Increase in Inventories | (47,956) | (28,932) | (14,094) |
| (Increase) decrease in prepaid expenses and other assets | (52,765) | (23,684) | 6,612 |
| Decrease in deferred revenue | (27,974) | (41,077) | (40,329) |
| Increase in accounts payable, accrued expenses and other liabilities | 136,684 | 10,979 | 50,016 |
| Total adjustments | 159,286 | (824,884) | 80,078 |
| Net cash provided by (used in) operating activities | 583,648 | (74,615) | (141,682) |
| Cash flows from investing activities: | |||
| Purchases of marketable securities | (577,278) | (470,393) | (240,391) |
| Sales or maturities of marketable securities | 378,146 | 439,209 | 426,356 |
| Purchase of restricted cash and marketable securities | 0 | (552) | (277) |
| Capital expenditures | (156,323) | (49,337) | (57,217) |
| Net cash (used in) provided by investing activities | (355,455) | (81,073) | 128,471 |
| Cash flows from financing activities: | |||
| Payments in connection with facility and capital lease obligations | (2,024) | (2,203) | (1,667) |
| Proceeds from issuance of Common Stock | 57,393 | 63,549 | 43,587 |
| Payments in connection with Common Stock tendered for employee tax obligations | (195,087) | (163,300) | (25,078) |
| Excess tax benefit from stock-based compensation | 216,857 | 4,308 | 0 |
| Proceeds in connection with issuance of convertible notes, net of debt issuance costs | 0 | 0 | 391,107 |
| Proceeds in connection with issuance of warrants | 0 | 0 | 93,800 |
| Payment in connection with purchase of convertible note hedges | 0 | 0 | (117,500) |
| Net cash provided by (used in) by financing activities | 77,139 | (97,646) | 384,249 |
| Net increase (decrease) in cash and cash equivalents | 305,332 | (253,334) | 371,038 |
| Cash and cash equivalents at beginning of period | 230,276 | 483,610 | |
| Cash and cash equivalents at end of period | 535,608 | 230,276 | 483,610 |
| Supplemental disclosure of cash flow information | |||
| Cash paid for interest | 23,842 | 21,946 | 14,725 |
| External Links | |
| REGENERON PHARMACEUTICALS, INC. (REGN) Fiscal Year 2013 | |
| Statements of 10-K in Excel | https://www.sec.gov/.../Financial.xlxs |
| Complete 10-K in HTML | https://www.sec.gov/.../10-K.html |
| Complete 10-K in XBRL | https://www.sec.gov/.../10-K-xbrl.zip |